文献速递炎症性肠病

炎症性肠病患者发生结核分枝杆菌感染的风险:韩国全国性人群研究

Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-07

基于韩国2011-2013年国民健康保险数据,评估炎症性肠病(IBD)患者活动性结核的发病率、标准化发病比和需筛查人数。IBD患者结核发病率为223.9/10万人年,标准化发病比为2.64;克罗恩病患者发病率显著高于溃疡性结肠炎患者。使用抗肿瘤坏死因子α(anti-TNF-α)治疗者结核风险显著升高,标准化发病比为6.53。

要点

  • IBD患者结核标准化发病比为2.64(2.30-3.01),需筛查人数为446.6(392.8-517.6)。
  • 克罗恩病患者结核发病率340.1/10万人年,显著高于溃疡性结肠炎患者的165.5/10万人年(P<0.001)。
  • 使用anti-TNF-α治疗的IBD患者结核标准化发病比为6.53(5.99-7.09),需筛查人数为180.5(144.6-240.1)。

核心结论

  • 临床医生应意识到接受抗肿瘤坏死因子α(anti-TNF-α)治疗的炎症性肠病患者活动性结核风险升高。

研究设计与样本

  • 基于韩国国民健康保险(NHI)系统2011-2013年数据的全国性人群研究。

主要发现

  • IBD患者结核发病率为223.9/10万人年,标准化发病比为2.64(2.30-3.01),需筛查人数为446.6(392.8-517.6)。
  • 克罗恩病患者结核发病率340.1/10万人年,显著高于溃疡性结肠炎患者的165.5/10万人年(P<0.001)。
  • 克罗恩病患者标准化发病比为4.00(3.59-4.45),需筛查人数为604.2(506.1-749.6);溃疡性结肠炎患者分别为1.95(1.66-2.27)和294.0(246.9-363.4)。
  • IBD患者结核发病率在年龄和性别间无显著差异(Ptrend=0.505,P=0.861)。
  • 使用5-氨基水杨酸、糖皮质激素、免疫调节剂和anti-TNF-α的IBD患者结核发病率分别为143.5、208.5、284.6和554.1/10万人年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The low incidence of Mycobacterium tuberculosis infection and lack of adequate controls have prevented researchers from estimating tuberculosis (TB) risk in inflammatory bowel disease (IBD) patients. AIM: To evaluate the risk of incident TB among IBD patients. METHODS: Using the 2011-2013 data of the South Korean National Health Insurance (NHI) system, we calculated the incidence rates (IRs), standardised incidence ratio (SIR) and number needed to screen (NNS) for incident TB in IBD patients compared to the general population in terms of subtype, age, gender and IBD medications. RESULTS: The IR, SIR and NNS for TB in IBD patients were 223.9/100 000 person-years, 2.64 (2.30-3.01) and 446.6 (392.8-517.6), respectively. The TB IR in Crohn's disease (CD) patients was significantly higher than that in ulcerative colitis (UC) patients (340.1/100 000 person-years vs. 165.5/100 000 person-years, respectively; P < 0.001). The SIR and NNS for TB among CD patients were 4.00 (3.59-4.45) and 604.2 (506.1-749.6), respectively; those among UC patients were 1.95 (1.66-2.27) and 294.0 (246.9-363.4). The TB IRs in IBD patients did not differ significantly by age or gender (Ptrend = 0.505 and P = 0.861, respectively). The TB IRs among IBD patients prescribed 5-ASA, corticosteroids, immunomodulators and anti-TNF-α were 143.5, 208.5, 284.6 and 554.1 per 100 000 person-years, respectively. Among IBD patients treated using anti-TNF-α, the TB IR was significantly higher than that among all IBD patients (P < 0.001); the SIR and NNS for TB were 6.53 (5.99-7.09) and 180.5 (144.6-240.1) respectively. CONCLUSION: Clinicians should be aware of the increased risk of active tuberculosis in patients with IBD who are receiving anti-TNF-α therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hong SN, Kim HJ, Kim KH, et al. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2016. PMID: 27933686. doi:10.1111/apt.13851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。